Moderna (MRNA) Reports Q3 EPS Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results
November 6, 2019 7:00 AM ESTPositive interim results announced from Phase 1 CMV vaccine (mRNA-1647) study
Positive interim results announced from Phase 1 mRNA encoding chikungunya antibody (mRNA-1944) study
First participant dosed in Phase 1b age de-escalation study of hMPV+PIV3 vaccine (mRNA-1653)
Cash, cash equivalents and investments at the end of the quarter were $1.34 billion, and are expected to be approximately $1.20 billion at the end of 2019
Net cash used in operating activities and purchases of property and equipment is expected to total approximately $500 million in 2019, and between... More
